A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

Jorge J Castillo, Shayna Sarosiek, Catherine A Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P Treon, Jorge J Castillo, Shayna Sarosiek, Catherine A Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P Treon

Abstract

The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 100 mg by mouth once daily in four-week cycles for up to 24 cycles. This study was registered under ClinicalTrials.Gov ID NCT04115059. Three participants were enrolled and received at least one cycle of dasatinib. The best response was stable disease. Two patients received 5 months and one patient received 1 month of therapy. The dose of dasatinib was decreased in one participant due to volume overload. Based on the lack of responses observed, the study was terminated. Dasatinib might not be effective in patients with WM progressing on ibrutinib.

Keywords: HCK; Waldenström macroglobulinemia; clinical trial; dasatinib.

Conflict of interest statement

Jorge J. Castillo received research funds and/or honoraria from Abbvie, AstraZeneca, Beigene, Casma, Cellectar, Janssen, Pharmacyclics, Polyneuron, Roche and TG Therapeutics. Shayna Sarosiek received research funds and/or honoraria Acrotech Biopharma, ADC Therapeutics and BeiGene from Steven P. Treon received research funds and/or honoraria from Abbvie, Beigene, BMS, Pharmacyclics and X4.

© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

References

    1. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122(7):1222–32.
    1. Dimopoulos MA, Tedeschi A, Trotman J, Garcia‐Sanz R, Macdonald D, Leblond V, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med. 2018;378(25):2399–410.
    1. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.
    1. Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50.
    1. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild‐type) MYD88‐mutated cells by a paracrine mechanism. Blood. 2018;131(18):2047–59.
    1. Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, et al. Natural history of Waldenstrom macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022;107(5):1163–71.
    1. Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127(25):3237–52.
    1. Liu X, Chen JG, Munshi M, Hunter ZR, Xu L, Kofides A, et al. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88‐driven B‐cell lymphomas. Blood Adv. 2020;4(1):141–153.
    1. Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, et al. SYK is activated by mutated MYD88 and drives pro‐survival signaling in MYD88 driven B‐cell lymphomas. Blood Cancer J. 2020;10(1):12.
    1. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, et al. Dasatinib (BMS‐354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007;6(4):1400–5.
    1. Owen RG, Treon SP, Al‐Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110–5.
    1. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–6.
    1. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):116–20.
    1. Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated Waldenstrom macroglobulinemia. J Clin Oncol. 2022;40(1):63–71.
    1. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B‐cell malignancies (BRUIN): A phase 1/2 study. Lancet. 2021;397(10277):892–901.
    1. Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to Noncovalent Bruton's tyrosine kinase inhibitors. N Engl J Med. 2022;386(8):735–43.
    1. Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, et al. The HCK/BTK inhibitor KIN‐8194 is active in MYD88‐driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021;138(20):1966–1979.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel